Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Inherited Metabolic Disease

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10545-006-0361-5PMID 16817011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standardized single breath normal values for carbon monoxide diffusing capacity.

  2015cited by this paper
• Cardiopulmonary Exercise Testing in Fabry Disease

  2005cited by this paper
• Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.

  2005cited by this paper
• Circulatory responses to exercise: are we misreading Fick?

  2005cited by this paper
• Fabry disease: overall effects of agalsidase alfa treatment

  2004cited by this paper
• Tissue Doppler imaging in Fabry disease

  2004cited by this paper
• Early Detection of Fabry Cardiomyopathy by Tissue Doppler Imaging

  2003cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease

  2001cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

  2001cited by this paper
• New insights in cardiac structural changes in patients with Fabry's disease.

  2000cited by this paper
• Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease

  2000cited by this paper
• Pulmonary involvement in Fabry disease.

  1997influential reference
• Cardiac output estimated noninvasively from oxygen uptake during exercise.

  1997cited by this paper
• The 1995 update of recommendations for a standard technique for measuring the single-breath carbon monoxide diffusing capacity (transfer factor)

  1996cited by this paper
• The 1995 update of recommendations for a standard technique for measuring the single-breath carbon monoxide diffusing capacity (transfer factor)

  1996cited by this paper
• Standardization of Spirometry, 1994 Update. American Thoracic Society.

  1995cited by this paper
• Lung function testing: selection of reference values and interpretative strategies.

  1992cited by this paper
• Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society.

  1991cited by this paper
• [Transvenous permanent pacemaker implantation for Fabry's disease. 3 cases report].

  1989cited by this paper
• PRINCIPLES OF EXERCISE TESTING AND INTERPRETATION

  1987influential reference
• Principles of Exercise Testing and Interpretation

  1987cited by this paper
• Electrocardiograms in Fabry's disease.

  1982cited by this paper
• Chronic airflow obstruction in Fabry's disease.

  1980cited by this paper
• Pulmonary involvement in Fabry's disease: a reappraisal follow-up of a San Diego kindred and review of literature.

  1972cited by this paper

• Physical Fitness and Physical Function in Patients With Fabry Disease: A Cross‐Sectional Multicentre Study

  2026cites this paper
• Pulmonary Manifestations of Lysosomal Storage Disorders in Adults.

  2025cites this paper
• Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review

  2025cites this paper
• Unveiling Functional Impairment in Fabry Disease: The Role of Peripheral vs. Cardiac Mechanisms

  2025cites this paper
• Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease

  2024cites this paper
• Respiratory impairments in patients suffering from Fabry disease – A cross-sectional study

  2024cites this paper
• How do Physical Activity and Exercise affect Fabry Disease? Exploring a New Opportunity.

  2024cites this paper
• Changes in peak oxygen consumption in Fabry disease and associations with cardiomyopathy severity

  2024cites this paper
• Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

  2021cites this paper
• Invisible burden of COVID-19: enzyme replacement therapy disruptions

  2021cites this paper
• Fabry Cardiomyopathy: Current Practice and Future Directions

  2021cites this paper
• Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued

  2020cites this paper
• Serial Analysis of Cardiopulmonary Fitness and Echocardiography in Patients with Fabry Disease Undergoing Enzyme Replacement Therapy

  2020influential citation
• Early initiation of enzyme replacement therapy in classical Fabry disease normalizes biomarkers in clinically asymptomatic pediatric patients

  2019cites this paper
• Cardiopulmonary fitness assessment on maximal and submaximal exercise testing in patients with Fabry disease

  2018cites this paper
• Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease.

  2018cites this paper
• Anderson-Fabry disease in heart failure

  2018cites this paper
• Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy.

  2017cites this paper
• Clinical characterisation of cardiac involvement in Anderson-Fabry Disease

  2016cites this paper
• The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations

  2016cites this paper
• Enzyme replacement therapy for Anderson-Fabry disease.

  2016cites this paper
• 56 – Treatment of “Other” Stroke Etiologies

  2016cites this paper
• Physical Exercise in Patients with Fabry Disease – a Pilot Study

  2016cites this paper
• Fabry disease, respiratory symptoms, and airway limitation – a systematic review

  2015influential citation
• Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

  2015cites this paper
• A systematic review to evaluate the effectiveness of enzyme replacement therapy for lysosomal storage disorders in comparison to the treatment of similar diseases with higher prevalence

  2014cites this paper
• Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

  2014cites this paper
• Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis

  2014cites this paper
• Pulmonary involvement in Fabry disease: overview and perspectives.

  2013cites this paper
• A Single Lung Transplant in a Patient with Fabry Disease: Causality or Far-Fetched? A Case Report

  2013cites this paper
• Fabry Disease: A Review of Ophthalmic and Systemic Manifestations

  2013cites this paper
• Pulmonary involvement in Anderson Fabry Disease

  2013cites this paper
• Heart Association/American Stroke Association Ischemic Attack : A Guideline for Healthcare Professionals From the American Guidelines for the Prevention of Stroke in Patients With Stroke or Transient

  2012cites this paper
• Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.

  2012cites this paper
• Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis

  2012influential citation
• Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals

  2011cites this paper
• Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association.

  2011cites this paper
• Enzyme replacement therapy for Fabry disease: some answers but more questions

  2011cites this paper
• Anderson-Fabry disease: a cardiomyopathy that can be cured.

  2011cites this paper
• 54 – Treatment of “Other” Stroke Etiologies

  2011cites this paper
• [Management of Fabry disease].

  2010cites this paper
• Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature

  2010cites this paper
• Pulmonary, Ear and Less Commonly Appreciated Manifestations

  2010cites this paper
• The Price of Care Versus the Cost of Caring

  2010cites this paper
• Cardiac challenges in patients with Fabry disease.

  2010cites this paper
• Cardiopulmonary involvement in Fabry’s disease

  2010cites this paper
• Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients

  2010cites this paper
• Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women

  2010cites this paper
• Enzyme Replacement Therapy for Fabry Disease

  2009cites this paper
• Fabry sykdom hos kvinner : Symptomer, organmanifestasjoner og livskvalitet

  2009cites this paper
• Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

  2008cites this paper
• Chapter 46 – Noncystic Hereditary Diseases of the Kidney

  2008cites this paper
• Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

  2008cites this paper
• Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage

  2008cites this paper
• Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life

  2007cites this paper
• Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy

  2007cites this paper